Takeda Pharmaceutical Q1 Earnings Call Highlights

1 month ago 25

MarketBeat

Thu, July 30, 2026 astatine 7:03 AM CDT 5 min read

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were successful enactment with its full-year outlook arsenic maturation from halfway brands and newer products mostly offset expected declines successful its mature portfolio.

Revenue totaled JPY 1.22 trillion, up 10.2% connected an existent foreign-exchange ground but down 0.5% astatine changeless speech rates, according to Chief Financial Officer Milano Furuta. Core operating nett was JPY 358.9 billion, rising 11.5% connected an existent FX ground and declining 0.5% astatine changeless speech rates. Reported operating nett was JPY 201.4 billion.

→ This Tiny AI Supplier Could Be More Important Than the Chipmakers

Time to bargain these 3 healthcare companies that raised gross guidance?

Core net per stock were JPY 154, down 11.8% astatine changeless speech rates, chiefly reflecting a favorable taxation presumption successful the anterior year. Reported EPS was JPY 72. The institution near its fiscal 2026 guidance unchanged and said it remains connected way to make JPY 650 cardinal to JPY 750 cardinal successful escaped currency travel for the year.

Core brands and caller launches offset portfolio unit

Core inline brands, which represented 58% of full revenue, grew 2.3% astatine changeless speech rates. Takeda said ENTYVIO, its largest product, grew 4% astatine changeless speech rates, portion immunoglobulin and albumin income were affected by U.S. shipment timing that was wrong the company's expectations.

→ Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?

Price Growth & Yield: For That Magical Combo, Leave the U.S.

Furuta said caller launches represented 4% of gross but grew 22.6% astatine changeless speech rates, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. Those gains helped antagonistic continued generic erosion for Vyvanse successful the U.S. and different loss-of-exclusivity and mature-product headwinds.

Takeda said first-quarter gross-profit show benefited principally from favorable FX effects connected plasma-derived therapies costs, peculiarly arsenic the euro strengthened against the U.S. dollar. Furuta said a one-time milestone related to a divestiture and exertion transportation made a comparatively tiny contribution. The institution continues to expect a full-year gross borderline of 65%.

→ Innovative ETF Strategies That Are Paying Off This Summer

Operating currency travel was beneath the prior-year level owed to working-capital changes related to its commercialized receivables factoring program. Adjusted escaped currency travel besides reflected a $200 cardinal outgo to Protagonist aft the spouse opted retired of a co-promotion statement for rusfertide. Takeda said it present has exclusive planetary improvement and commercialization rights for rusfertide.

Read Entire Article